Thank you #AHAJournals for the opportunity to serve as Social Media Editor!

4/ 🌟TAVR has demonstrated safety and efficacy as an alternative to surgical intervention in lower-risk patients aged 60 to 75 with tricuspid AS, showing comparable outcomes to surgery over a three-year follow-up period, along with superior hemodynamic performance

3/ At 3 years:
🫀Similar rates of structural valve deterioration (≥moderate) 4.5% TAVR vs 5.2% surgery;
🫀Lower rates of bioprosthetic valve dysfunction with TAVR (11.9% vs. 21%);
🫀Similar rates of bioprosthetic valve failure (1.6% vs 2.9%).

2/
🫀Primary composite (death, stroke or valve/procedure/HF related hospitalization): 16.1% TAVR vs 12.6% surgery -> no significant difference.
🫀In bicuspid valve patients, outcomes favored surgery, though not statistically significant. #SoMeEditor #CardioTwitter #TAVR